Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: alefacept, siplizumab | 0.81 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 1 stopped | 0.60 |
| literature PubMed | 14 Parkinson's papers of 19,594 | 0.64 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7728
Sealed predictions
- CD2 in dopamine neurons, braak-0.30 (p 0.428) → +0.22 (p 0.569)receipt 7735
Swarm cases
receipt 7735: CD2 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.413, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.246, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.27 (p 0.277, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.12, sign flips 0; without severely affected donors -0.21 (p 0.413, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts